Other

Praxis Precision Medicines, Inc.

Cavion, Inc.

Biogen Ma Inc.

Combinatorx, Incorporated

Margaret S Lee

Kiran Reddy

Muralikrishna Duvvuri

Michelle S Higgin

Mahesh Padval

Bruce N Rehlaender

Randall Wagner

Sapna Makhija Garad

Evan Newbold

Spyridon Papapetropoulos

Gabriel Maurice Belfort

Donna Lee Romero

Curtis Keith

Marc Roger De Ryck

Grant R Zimmermann

Rafal Kaminski

M James Nichols

Marion Wittmann

Sharon Tamir

Benoit Kenda

Karine Leclercq

Alyce L Finelli

Glenn F Short, Iii

Daniel Grau

This invention relates to methods and materials for treating mammals having, or at risk of developing, one or more movement disorders (e.g., essential tremor, epilepsy, and/or Parkinson's disease). For example, compositions including one or more T-type calcium channel antagonists (e.g., one or more Cav3 antagonists such as CX-8998) are provided, as well as methods for administering such compositions to a mammal having, or at risk of developing, one or more movement disorders (e.g., essential tremor, epilepsy, and/or Parkinson's disease) to treat the mammal.

Treating essential tremor using (R)-2-(4-Isopropylphenyl)-N-(1-(5-(2,2,2-Trifluoroethoxy)pyridin-2-yl)ethyl)acetamide

Described herein, in part, are dosage forms and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a T-type calcium channel, such as epilepsy and epilepsy syndromes (e.g., absence seizures, juvenile myoclonic epilepsy, or a genetic epilepsy), tremor (e.g., essential tremor), and psychiatric disorder (e.g., mood disorders (e.g., major depressive disorder)). The present invention further comprises methods for modulating the function of a T-type calcium channel.

Formulations of T-type calcium channel modulators and methods of use thereof

The invention generally relates to the use of nuclear transport modulators, e.g., CRM1 inhibitors, of Formula (I) for treating epilepsy in a subject. Subjects can have unprovoked seizures without prior warning that affect one or both hemispheres of the brain. The disclosed methods can reduce the severity and occurrence of these unprovoked epileptic seizures and can result in resolution of epilepsy. The method comprises administering to the subject an effective amount of a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof. 

CRM1 inhibitors for treating epilepsy

Treating essential tremor using (R)-2-(4-Isopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide

The invention relates to compounds useful in treating conditions associated with voltage-gated ion channel function, particularly conditions associated with sodium channel activity. More specifically, the invention concerns heterocyclic compounds (e.g., compounds according to any of Formulas (I)-(III) or Compounds (1)-(65) of Table 1) that are that are useful in treatment of conditions such as epilepsy, cancer, pain, migraine, Parkinson's Disease, mood disorders, schizophrenia, psychosis, tinnitus, amyotropic lateral sclerosis, glaucoma, ischaemia, spasticity disorders, obsessive compulsive disorder, restless leg syndrome and Tourette syndrome.

Heterocyclic inhibitors of the sodium channel

The invention features compositions, methods, and kits for the treatment of metabolic disorders such as diabetes and obesity.

Methods and reagents for the treatment of metabolic disorders

A thong underpant which may be combined with a full sanitary napkin, and a method of making the same; the pad may be formed integrally with the disposable thong underpant, or the back end of the sanitary napkin affixed, as by sewing, to the stretched thong, or the front panel of the thong may be continued into the crotch region to form a partial crotch panel, just big enough to receive the adhesive on the underside of a generally rectangular sanitary napkin.

Disposable thong underwear

Growing community of inventors

Middleton, MA, United States of America

Margaret S Lee